Psychiatry/Psychology | Phase I Developments | UNITED STATES

Neurana Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Neurana Pharmaceuticals Announces Publication of a Driving Study Demonstrating the Effects of Tolperisone

Lead Product(s): Tolperisone

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

The publication reports results from the Phase 1, threeway, randomized, blinded, three-period crossover study that evaluated cyclobenzaprine in neuromuscular conditions.

Cadent Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing

Lead Product(s): CAD-9303

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Cowen Healthcare Investments

Deal Size: $15.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing April 29, 2020

Details:

The Company plans to allocate all proceeds to continue development for its lead cognitive disorder asset, CAD-9303 for the treatment of the cognitive deficits and negative symptoms of schizophrenia.

Navitor Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

Lead Product(s): NV-5138

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Supernus Pharmaceuticals

Deal Size: $525.0 million? Upfront Cash: $25.0 million

Deal Type: Licensing Agreement April 21, 2020

Details:

Under the terms of the agreement, Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in treatment-resistant depression (TRD).

Mind Medicine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

Lead Product(s): 18-Methoxycoronaridine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

Data from the current human study is expected to help advance the planning and design of MindMed's future trials of 18-MC in opioid use disorder patients.

Seelos Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

Lead Product(s): Ketamine Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

Interim data disclosed includes the hemodynamic (vital signs) side effect profile to address the known and expected side effects of ketamine, which are increases in blood pressure and heart rate.

Seelos Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

Lead Product(s): Ketamine Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

Interim data from both studies has demonstrated that doses of 30mg, 60mg, 75mg and 90mg of SLS-002 have been generally safe and well-tolerated.

Cerevel Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder

Lead Product(s): CVL-936

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of CVL-936 in healthy volunteers ages 18 to 50.

DemeRx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

Lead Product(s): Ibogaine Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: ATAI Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Investment January 24, 2020

Details:

The investment aims at developing treatment protocol for safety of patients who are taking ibogaine for treatment of opioid use disorder (OUD).

GABA Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

GABA Therapeutics commences phase I study of Etifoxine

Lead Product(s): Etifoxine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2020

Details:

Data from this study could provide important insights for a broad range of neurological disorders beyond anxiety and depression.

Find

Find Psychiatry/Psychology Drugs in Phase I Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces Publication of a Driving Study Demonstrating the Effects of Tolperisone

Cadent Therapeutics

Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing

Navitor Pharmaceuticals

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

Mind Medicine

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

Seelos Therapeutics

Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

Seelos Therapeutics

Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

Cerevel Therapeutics

Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder

DemeRx

ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

GABA Therapeutics

GABA Therapeutics commences phase I study of Etifoxine